NEWS BITES ASIAN MARKETS
Ryman Healthcare Limited (NZSX:RYM), New Zealand's largest finance & other services company by market capitalisation, increased 5.0c (or 1.0%) to close at NZD4.82. In the past week the shares have lifted 3.9%, the biggest trailing week gain since December 18. Compared with the NZX 50 Index, which rose 8.0 points (or 0.2%) on the day, this was a relative price change of 0.9%.
Bullish Signals
Uptrend
- The stock rose 1.0%, for a 2-day rise of 1.5%, on high volatility today and expanding price range.
- The stock hit a year-high 8th time in three months.
- The stock's relative price strength percentile is rising at 67 for 6 months, 69 for 3 months and 76 for 1 month.
- The price lifted 3.9% in the last week and 3.7% in the last month.
- Compared with the NZX 50 Index which rose 0.2% for the week and 3.3% for the month, this represented a relative price increase of 3.7% for the week and 0.3% for the month.
- In the last three months the stock has hit a new 52-week high eight times, pointing to a significant uptrend.
- The present value of NZD1,000 (PV1000) invested one year ago is NZD1,691, including a capital gain of NZD651 and dividend reinvested of NZD40.
PV1000 | 1-week | 1-month | 1-year |
RYM.NZSX | 1,039 | 1,037 | 1,691 |
NZX 50 Index | 1,002 | 1,033 | 1,253 |
Fundamental measures by comparison with the sector average [in brackets] indicate Undervaluation:
- Price to Book of 3.7 [4.6]. We estimate the shares are trading at a current year Price to Book of 3.1 and a forward year Price to Book of 2.6.
- Return on Equity 18.7% [2.0%].
Other Bullish Signals:
- Interest cover defined by EBIT/I is 19.4 times. This indicates it is less leveraged.
- Tobin's Q Ratio, defined as MCap divided by Total Assets, is 1.3. Compared with the rest of the market the stock is undervalued.
Description | Value | Rank In Market |
Net Profit Margin % | 47 | In Top Quartile |
EBITDA Margin % | 56.1 | In Top Quartile |
MCap | US$2 billion | In Top Quartile |
Price/MAP200 | 1.19 | In Top Quartile |
Interest Cover | 19.4 | In Top Quartile |
Note
Volume: there were 356,050 shares worth NZD1.7 million (US$1.4 million) traded. The volume was 0.7 times the average trading of 490,644 shares.
Beta: the Beta of this stock is 0.3. A Beta lower than 1 suggests this is a low risk, low return stock with volatility less than that of the market.
Fundamental measures by comparison with the sector average [in brackets] indicate Overvaluation:
- Price/Sales of 9.4 [4.8].
- Dividend yield of 1.9% [2.2%].
Bearish Signals:
- Total Liabilities/ EBITDA of 8.8 is more than or equal to 5, this compares unfavourably with the Joseph Piotroski benchmark of 5.
COMPANY ANNOUNCEMENTS
The last 7 company announcements are:
February 07: Ryman Healthcare: Disclosure of Directors and Officers Relevant Interests
